Buffett's Berkshire Hathaway strikes $9.7 billion deal for Occidental's OxyChem unit

Berkshire Hathaway is acquiring Occidental Petroleum's OxyChem unit for $9.7 billion in cash, its largest takeover since 2022, significantly aiding Occidental in reducing its substantial $23.34 billion debt and allowing it to refocus on core oil and gas operations. This transaction deepens Berkshire's existing 28.2% stake in Occidental and deploys a portion of its record $344 billion cash reserves, with analysts largely viewing it as a strategic "big bang" deleveraging move for Occidental, despite some acknowledged trade-offs regarding OxyChem's future free cash flow.

Analysis

Berkshire Hathaway's $9.7 billion cash acquisition of Occidental Petroleum's OxyChem unit represents a significant strategic move for both companies. For Occidental, this transaction is a critical step towards repairing its balance sheet, which was burdened with $23.34 billion in debt following its acquisitions of Anadarko and CrownRock. The proceeds will facilitate a substantial deleveraging, a move described by JP Morgan analysts as a "big bang" positive for the equity, and allow the company to refocus on its core oil and gas operations, which accounted for 75% of its earnings last year. The sale price appears favorable, exceeding TPH & Co's carrying value estimate of $8.3 billion, and strategically divests an asset with a weakening near-term outlook; Occidental had recently lowered OxyChem's pre-tax income guidance to between $800 million and $900 million, with analysts noting its free cash flow prospects for 2025 had dimmed. For Berkshire Hathaway, the deal deepens its commitment to Occidental, in which it already holds a 28.2% stake, and effectively deploys a fraction of its record $344 billion cash reserve. The transaction, stewarded by incoming CEO Greg Abel, confirms Berkshire's long-term conviction in Occidental's energy-focused strategy.

Key Decisions for Investors

• Investors in Occidental Petroleum should view this transaction as a significant derisking event, as the $9.7 billion cash infusion provides a clear path to reducing its $23.34 billion debt burden and may warrant a re-evaluation of the stock's risk profile.
• While the sale strengthens Occidental's balance sheet, investors must now assess the company as a more concentrated oil and gas pure-play, increasing its sensitivity to energy price volatility and operational performance in its core assets.
• For Berkshire Hathaway shareholders, the deal is less about the immediate financial impact of OxyChem and more a confirmation of its long-term strategic investment thesis in Occidental, demonstrating a continued willingness to deploy capital in support of its key holdings.